Clinical Trials Logo

Chemo-refractory Melanoma clinical trials

View clinical trials related to Chemo-refractory Melanoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT01216657 Terminated - Clinical trials for Chemo-refractory Melanoma

Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma

Start date: March 2009
Phase: Phase 2
Study type: Interventional

Sunitinib is a novel small molecule receptor tyrosine kinase inhibitor with direct antitumor effects as well as antiangiogenetic activity. Preclinical and clinical data for Sunitinib and data about angiogenesis and growth regulation in melanoma suggest the activity of Sunitinib in melanoma. This study will investigate the efficacy, safety and tolerability of Sunitinib as palliative treatment in chemo-refractory metastatic melanoma.